In the interest of full disclosure

Lancet Oncol. 2010 Apr;11(4):314-5; author reply 315. doi: 10.1016/S1470-2045(10)70044-9.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Bias
  • Biomarkers, Pharmacological
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics*
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / pharmacology
  • Doxorubicin / administration & dosage
  • Doxorubicin / pharmacology
  • Female
  • Fluorouracil / administration & dosage
  • Fluorouracil / pharmacology
  • Gene Expression Profiling*
  • Humans
  • Survival Analysis*
  • Tamoxifen / administration & dosage
  • Tamoxifen / pharmacology

Substances

  • Biomarkers, Pharmacological
  • Tamoxifen
  • Doxorubicin
  • Cyclophosphamide
  • Fluorouracil